Business context and reporting period
The supplied filing is Adtalem Global Education Inc.’s Form 10-Q, filed January 30, 2024, for the quarter and six months ended December 31, 2023 (Adtalem fiscal 2024 Q2). This does not match the request metadata identifying Covista Inc. or “2023 Q2”; verify the issuer and period before relying on this summary. Adtalem operates Chamberlain University, Walden University, and medical and veterinary schools AUC, RUSM, and RUSVM.
Financial performance and condition
Amounts below are in millions of dollars except per-share data. Comparisons are with the corresponding prior-year period; prior-year figures were revised in the filing.
| Metric | Three months ended Dec. 31, 2023 | Six months ended Dec. 31, 2023 |
|---|---|---|
| Revenue | $393.2; +8.4% | $762.1; +6.3% |
| Operating income / margin | $58.6 / 14.9%; +28.7% | $86.8 / 11.4%; +25.5% |
| Net income | $39.9; versus $24.7 | $50.5; versus $25.2 |
| Diluted EPS | $0.98; versus $0.53 | $1.22; versus $0.55 |
| Adjusted net income (non-GAAP) | $50.3; down 6.5% | $89.6; versus $95.4 |
| Adjusted diluted EPS (non-GAAP) | $1.23; versus $1.17 | $2.16; versus $2.06 |
| Operating cash flow, continuing operations | Not presented separately for the quarter | $83.1; versus $42.3 |
- Quarter revenue grew at Chamberlain (+8.6%), Walden (+11.3%), and Medical and Veterinary (+3.8%). For the six months, growth was 7.0%, 9.7%, and approximately flat, respectively.
- Quarter GAAP operating margin improved, while adjusted operating income fell 3.0% to $75.6 million and adjusted operating margin declined to 19.2% from 21.5%. Management cited higher labor, marketing, bad-debt, incentive compensation, and growth-related costs. Adjusted measures are non-GAAP.
- Cash and cash equivalents were $182.9 million at December 31, down from $273.7 million at June 30, 2023. Total current assets were $378.1 million and current liabilities $398.6 million.
- Six-month capital expenditures were $30.3 million, versus $9.7 million. Management expects fiscal 2024 capital spending of $50–$60 million.
- Debt principal was $708.3 million: $405.0 million of 5.50% secured notes due 2028 and $303.3 million Term Loan B. The Term Loan B rate was 9.47% at December 31. The $400 million revolver had $165.9 million available, with no revolver borrowings reported.
- Six-month financing cash outflow was $151.4 million, including $160.5 million of share repurchases. The company repurchased 3.51 million shares during the six months at an average $45.93 per share.
Material changes, outlook, risks and unusual items
- GAAP earnings increased substantially, aided by revenue growth and lower restructuring, integration, and intangible amortization expenses, as well as the absence of the prior-year $5.0 million investment impairment. Adjusted net income declined in the quarter despite higher adjusted EPS, which benefited from fewer weighted-average shares after repurchases.
- Walden enrollment was up 7.9% year over year at December 31; Chamberlain’s November session enrollment was up 6.6%. Medical and Veterinary enrollment was down 7.5% for the September 2023 semester. Management attributed Walden’s enrollment turnaround to marketing differentiation and enrollment, marketing, and admissions improvements.
- Management expects additional Walden integration expense through the remainder of fiscal 2024. The filing does not provide clear full-year revenue or earnings guidance.
- After quarter-end, on January 26, 2024, Adtalem prepaid $50.0 million of Term Loan B and repriced the loan, reducing its applicable interest margin by 0.50 percentage points. On January 19 it announced a new share repurchase authorization of up to $300 million.
- Title IV oversight is a significant regulatory risk. ED assigned Adtalem a 0.2 fiscal 2022 composite score; its institutions may continue participating provisionally with heightened cash monitoring and reporting. Adtalem delivered a $157.9 million letter of credit. Additional letters of credit of $84.0 million and $76.2 million support Walden’s Title IV participation. Management said it does not expect these conditions to materially adversely affect operations.
- New Gainful Employment rules take effect July 1, 2024; Adtalem is assessing their potential effect. The 90/10 rule also applies to its proprietary institutions. Fiscal 2023 Title IV revenue percentages under the then-current calculation ranged from 65% to 87% by institution.
- A Walden class action settlement was tentatively agreed at $28.5 million, subject to non-financial terms, Board and court approval; the company recorded a $28.5 million accrual. Adtalem sought $5.5 million of indemnification from Walden’s former owner. A separate $18.5 million litigation reserve is identified in the six-month operating-income reconciliation; the filing does not clearly establish its relationship to the $28.5 million accrual.
- Adtalem revised comparative financial statements after identifying a scholarship revenue-recognition error in Medical and Veterinary: future tuition discounts constituting material rights should have been accounted for as separate performance obligations. It concluded prior periods were not materially misstated and no amended filings were required. The filing also reports a $0.6 million write-down of a building held for sale.
- A short-seller report published January 30, 2024 alleged misconduct, adversely affected the share price, and could prompt litigation or regulatory investigations, according to the filing. The company reports effective disclosure controls as of December 31, 2023.
Most important facts for investors to verify
- Confirm that this Adtalem / ATGE filing—not a Covista filing—is the intended document and that the relevant reporting period is fiscal Q2 2024.
- Track ED’s provisional certification, heightened cash monitoring, letters of credit, composite-score status, and outcomes of pending program recertifications.
- Monitor the Walden class action settlement approval, any indemnification recovery, and the nature and financial impact of the separately disclosed litigation reserve.
- Assess whether enrollment growth and pricing can offset rising operating costs and weaker adjusted operating income, particularly at Chamberlain and Medical and Veterinary.
- Verify the post-quarter debt prepayment and repricing, revolver availability after letters of credit, and execution of capital spending and buyback plans.
- Review the effect of the revised scholarship accounting on future revenue timing and the potential effect of Gainful Employment rules.